Skip to content
Search

Latest Stories

Submit Guest Post

India’s tax council to decide on rate cut for Covid essentials on June 12

India’s tax council to decide on rate cut for Covid essentials on June 12

INDIA’S Goods and Services Tax (GST) Council will meet on June 12 to decide on rate cut for Covid essentials and black fungus medicine, according to officials.

The meeting will be chaired by finance minister Nirmala Sitharaman.


In the previous meeting, held on May 28, the council had formed a Group of Ministers (GoM) to recommend tax relief on Covid essentials, including PPE kits, masks and vaccines.

The GoM submitted its report to the council on June 7.

The GoM was mandated to examine whether a rate cut or exemption is required for Covid relief items like medical-grade oxygen, pulse oximeters, hand sanitizers, oxygen therapy equipment, PPE kits, N-95 and surgical masks.

The panel also looked into testing kits, vaccines, drugs, and medicines for Covid treatment.

GST Council that has state ministers as members, is the governing body for the implementation of GST rules in India.

On May 28, the council exempted GST on import of Amphotericin B – a medicine used for treatment of black fungus.

Currently, 5 per cent GST is levied on domestically manufactured vaccines, while it is 12 per cent for Covid drugs and oxygen concentrators.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less